NK Cell Therapy Pipeline

(Las Vegas, Nevada, United States) “NK Cell Therapy Pipeline Insight, 2023″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the NK Cell Therapy Market.

The NK Cell Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Click here to know more about the NK Cell therapy in different phases of development – NK Cell therapy pipeline assessment

Some of the key takeaways from the NK Cell Therapy Pipeline Report:

• Companies across the globe are diligently working toward developing novel NK Cell Therapy treatment therapies with a considerable amount of success over the years. 
• NK Cell Therapy companies working in the treatment market are ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivaxm, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, Bellicum Pharmaceuticals, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, Affimed Therapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect, Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), GT Biopharma (formerly Oxis International Inc.), Nektar Therapeutics, Artiva Biotherapeutics, Senti Biosciences, oNKo-innate, Affimed Therapeutics, Agenus, Chongqing Sidemu Biotechnology, NKGen Biotech, Caribou Biosciences, Gamida-Cell, Wugen, Molmed, Century Therapeutics, KSQ Therapeutics, GT Biopharma, Shoreline Biosciences, Indapta Therapeutics, HebeCell, Sorrento therapeutics, Appia Bio,  Cellatoz  Therapeutics, Sanofi, Glycotype, CiMaas, CoImmune, Editas Medicine, Healios, Chimeric Therapeutics, Rubius Therapeutics, Oncternal Therapeutics, MedXCell, MiNK Therapeutics, Phio Pharmaceuticals, Biohaven Pharmaceuticals, Lava therapeutics, Allogene Therapeutics/Notch Therapeutics, Onward therapeutics, Miltenyi Biotech and others, are developing therapies for the NK Cell Therapy treatment 

• Emerging NK Cell Therapy therapies such as – NKTR-214, Monalizumab, Bemarituzumab, ALT 803, CellProtect, K-NK002, NK-92, WU-NK-101, ALECSAT, Anti-CD33 CAR-NK cells, and others are expected to have a significant impact on the NK Cell Therapy market in the coming years.   

NK Cell Therapy Overview

Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cells have cytotoxic small granules, which contain special proteins such as perforins and proteases, are known as granzymes in their cytoplasm. Perforins form pores in the cell membrane of the target cell through which the granzymes and associated molecules induce apoptosis.

Get a Free Sample PDF Report to know more about NK Cell Therapy Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight

Emerging NK Cell Therapy Drugs Under Different Phases of Clinical Development Include:

• NKTR-214: Nektar therapeutics
• Monalizumab: Innate Pharma
• Bemarituzumab: Five Prime Therapeutics
• ALT 803: ImmunityBio     
• CellProtect: XNK Therapeutics
• K-NK002: Kiadis Pharma
• NK-92: ImmunityBio
• And others 

Route of Administration

NK Cell Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

NK Cell Therapy Pipeline Therapeutics Assessment

• NK Cell Therapy Assessment by Product Type
• NK Cell Therapy By Stage and Product Type
• NK Cell Therapy Assessment by Route of Administration
• NK Cell Therapy By Stage and Route of Administration
• NK Cell Therapy Assessment by Molecule Type
• NK Cell Therapy by Stage and Molecule Type

DelveInsight’s NK Cell Therapy Report covers around 185+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further NK Cell Therapy product details are provided in the report. Download the NK Cell Therapy pipeline report to learn more about the emerging NK Cell Therapy therapies – https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight

NK Cell Therapy Pipeline Analysis:

The NK Cell Therapy pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of NK Cell Therapy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NK Cell Therapy Treatment.
• NK Cell Therapy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• NK Cell Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NK Cell Therapy market.

Download Sample PDF Report to know more about NK Cell Therapy drugs and therapies – https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight

Scope of NK Cell Therapy Pipeline Drug Insight    

• Coverage: Global
• Key NK Cell Therapy Companies: ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivaxm, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, Bellicum Pharmaceuticals, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, Affimed Therapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect, Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), GT Biopharma (formerly Oxis International Inc.), Nektar Therapeutics, Artiva Biotherapeutics, Senti Biosciences, oNKo-innate, Affimed Therapeutics, Agenus, Chongqing Sidemu Biotechnology, NKGen Biotech, Caribou Biosciences, Gamida-Cell, Wugen, Molmed, Century Therapeutics, KSQ Therapeutics, GT Biopharma, Shoreline Biosciences, Indapta Therapeutics, HebeCell, Sorrento therapeutics, Appia Bio,  Cellatoz  Therapeutics, Sanofi, Glycotype, CiMaas, CoImmune, Editas Medicine, Healios, Chimeric Therapeutics, Rubius Therapeutics, Oncternal Therapeutics, MedXCell, MiNK Therapeutics, Phio Pharmaceuticals, Biohaven Pharmaceuticals, Lava therapeutics, Allogene Therapeutics/Notch Therapeutics, Onward therapeutics, Miltenyi Biotech and others
• Key NK Cell Therapy Therapies: NKTR-214, Monalizumab, Bemarituzumab, ALT 803, CellProtect, K-NK002, NK-92, WU-NK-101, ALECSAT, Anti-CD33 CAR-NK cells, and others
• NK Cell Therapy Therapeutic Assessment: NK Cell Therapy current marketed and NK Cell Therapy emerging therapies
• NK Cell Therapy Market Dynamics: NK Cell Therapy market drivers and NK Cell Therapy market barriers 

Request for Sample PDF Report for NK Cell Therapy Pipeline Assessment and clinical trials – https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight

Table of Contents

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting